FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310549999> ?p ?o ?g. }

• W4310549999 endingPage "e005732" @default.
• W4310549999 startingPage "e005732" @default.
• W4310549999 abstract "As management and prevention strategies against COVID-19 evolve, it is still uncertain whether prior exposure to immune checkpoint inhibitors (ICIs) affects COVID-19 severity in patients with cancer.In a joint analysis of ICI recipients from OnCovid (NCT04393974) and European Society for Medical Oncology (ESMO) CoCARE registries, we assessed severity and mortality from SARS-CoV-2 in vaccinated and unvaccinated patients with cancer and explored whether prior immune-related adverse events (irAEs) influenced outcome from COVID-19.The study population consisted of 240 patients diagnosed with COVID-19 between January 2020 and February 2022 exposed to ICI within 3 months prior to COVID-19 diagnosis, with a 30-day case fatality rate (CFR30) of 23.6% (95% CI 17.8 to 30.7%). Overall, 42 (17.5%) were fully vaccinated prior to COVID-19 and experienced decreased CFR30 (4.8% vs 28.1%, p=0.0009), hospitalization rate (27.5% vs 63.2%, p<0.0001), requirement of oxygen therapy (15.8% vs 41.5%, p=0.0030), COVID-19 complication rate (11.9% vs 34.6%, p=0.0040), with a reduced need for COVID-19-specific therapy (26.3% vs 57.9%, p=0.0004) compared with unvaccinated patients. Inverse probability of treatment weighting (IPTW)-fitted multivariable analysis, following a clustered-robust correction for the data source (OnCovid vs ESMO CoCARE), confirmed that vaccinated patients experienced a decreased risk of death at 30 days (adjusted OR, aOR 0.08, 95% CI 0.01 to 0.69).Overall, 38 patients (15.8%) experienced at least one irAE of any grade at any time prior to COVID-19, at a median time of 3.2 months (range 0.13-48.7) from COVID-19 diagnosis. IrAEs occurred independently of baseline characteristics except for primary tumor (p=0.0373) and were associated with a significantly decreased CFR30 (10.8% vs 26.0%, p=0.0462) additionally confirmed by the IPTW-fitted multivariable analysis (aOR 0.47, 95% CI 0.33 to 0.67). Patients who experienced irAEs also presented a higher median absolute lymphocyte count at COVID-19 (1.4 vs 0.8 109 cells/L, p=0.0098).Anti-SARS-CoV-2 vaccination reduces morbidity and mortality from COVID-19 in ICI recipients. History of irAEs might identify patients with pre-existing protection from COVID-19, warranting further investigation of adaptive immune determinants of protection from SARS-CoV-2." @default.
• W4310549999 created "2022-12-12" @default.
• W4310549999 creator A5001343667 @default.
• W4310549999 creator A5009968141 @default.
• W4310549999 creator A5015437737 @default.
• W4310549999 creator A5015509025 @default.
• W4310549999 creator A5015546743 @default.
• W4310549999 creator A5019053015 @default.
• W4310549999 creator A5020684039 @default.
• W4310549999 creator A5022151942 @default.
• W4310549999 creator A5026708766 @default.
• W4310549999 creator A5027094790 @default.
• W4310549999 creator A5030985565 @default.
• W4310549999 creator A5031803742 @default.
• W4310549999 creator A5031805867 @default.
• W4310549999 creator A5034412136 @default.
• W4310549999 creator A5035175323 @default.
• W4310549999 creator A5036133691 @default.
• W4310549999 creator A5043051104 @default.
• W4310549999 creator A5045454738 @default.
• W4310549999 creator A5046117778 @default.
• W4310549999 creator A5050187820 @default.
• W4310549999 creator A5051894396 @default.
• W4310549999 creator A5052808201 @default.
• W4310549999 creator A5053524419 @default.
• W4310549999 creator A5055480892 @default.
• W4310549999 creator A5059012958 @default.
• W4310549999 creator A5059519339 @default.
• W4310549999 creator A5060954139 @default.
• W4310549999 creator A5063300526 @default.
• W4310549999 creator A5065961744 @default.
• W4310549999 creator A5066059934 @default.
• W4310549999 creator A5067643297 @default.
• W4310549999 creator A5071929183 @default.
• W4310549999 creator A5072284989 @default.
• W4310549999 creator A5073079268 @default.
• W4310549999 creator A5074076730 @default.
• W4310549999 creator A5075514238 @default.
• W4310549999 creator A5079807284 @default.
• W4310549999 creator A5080958850 @default.
• W4310549999 creator A5082293621 @default.
• W4310549999 creator A5087448111 @default.
• W4310549999 creator A5088145681 @default.
• W4310549999 creator A5089513581 @default.
• W4310549999 creator A5076627681 @default.
• W4310549999 date "2022-11-01" @default.
• W4310549999 modified "2023-10-08" @default.
• W4310549999 title "Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries" @default.
• W4310549999 cites W2781484625 @default.
• W4310549999 cites W2908586015 @default.
• W4310549999 cites W2984467945 @default.
• W4310549999 cites W2996181407 @default.
• W4310549999 cites W3007940623 @default.
• W4310549999 cites W3013894953 @default.
• W4310549999 cites W3024048796 @default.
• W4310549999 cites W3034366532 @default.
• W4310549999 cites W3037848912 @default.
• W4310549999 cites W3041356098 @default.
• W4310549999 cites W3046013618 @default.
• W4310549999 cites W3046619251 @default.
• W4310549999 cites W3096762544 @default.
• W4310549999 cites W3105486497 @default.
• W4310549999 cites W3106005610 @default.
• W4310549999 cites W3120798586 @default.
• W4310549999 cites W3123130740 @default.
• W4310549999 cites W3125966940 @default.
• W4310549999 cites W3134655285 @default.
• W4310549999 cites W3145657260 @default.
• W4310549999 cites W3149529669 @default.
• W4310549999 cites W3171785263 @default.
• W4310549999 cites W3173353757 @default.
• W4310549999 cites W3184240249 @default.
• W4310549999 cites W3199172037 @default.
• W4310549999 cites W3201366056 @default.
• W4310549999 cites W3210005297 @default.
• W4310549999 cites W3214754805 @default.
• W4310549999 cites W4200427880 @default.
• W4310549999 cites W4206697524 @default.
• W4310549999 cites W4223527551 @default.
• W4310549999 cites W4224920933 @default.
• W4310549999 cites W4226343533 @default.
• W4310549999 cites W4229332259 @default.
• W4310549999 cites W4280575245 @default.
• W4310549999 cites W4281388042 @default.
• W4310549999 cites W4281648196 @default.
• W4310549999 cites W4283019343 @default.
• W4310549999 cites W4283315173 @default.
• W4310549999 doi "https://doi.org/10.1136/jitc-2022-005732" @default.
• W4310549999 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36450384" @default.
• W4310549999 hasPublicationYear "2022" @default.
• W4310549999 type Work @default.
• W4310549999 citedByCount "1" @default.
• W4310549999 countsByYear W43105499992023 @default.
• W4310549999 crossrefType "journal-article" @default.
• W4310549999 hasAuthorship W4310549999A5001343667 @default.
• W4310549999 hasAuthorship W4310549999A5009968141 @default.
• W4310549999 hasAuthorship W4310549999A5015437737 @default.
• W4310549999 hasAuthorship W4310549999A5015509025 @default.

• next